VERA — Vera Therapeutics, Inc. (Stock)

Price: $29.88 · 1 day: +0.50% · 5 days: -1.78% · 1 month: -11.55% · YTD: -41.00%
As of 2026-10-09 20:00 UTC.

52-week range: $23.05 – $56.05 (currently at 21% of the range).

The read

VERA is in a downtrend, momentum soft. $30 is the level overhead; $25 the first support below.

6 of 6 technical checks lean bearish.

• Price vs 50-day: below
• Price vs 200-day: below
• 50d vs 200d avg: below
• MACD: bearish
• RSI momentum: 30
• 5-day tape: -1.8%

Key levels

Indicators

Next earnings: 2026-11-05.

Latest VERA news

• Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight — DelveInsight forecasts the paroxysmal nocturnal hemoglobinuria (PNH) market across the 7MM (US, EU4, UK, Japan) to grow from approximately USD 1.5 billion in 2025 at a 7.1% CAGR through 2036, driven by new complement-tar (PR Newswire, 2026-09-17)
• Biotech Pulls A Major Chart Upset -- What Happened? — Vera Therapeutics' stock surged on Tuesday following positive clinical trial results for its kidney disease treatment Trutakna, which demonstrated significant improvements in eGFR rates among patients with IgA nephropath (Investor's Business Daily, 2026-09-15)
• Vera Therapeutics, Inc. — Form 8-K: 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits — # Summary Vera Therapeutics, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing information under Regulation FD provisions regarding other events and financial statements. The filing does not contain s (SEC EDGAR, 2026-09-15)
• Vera Therapeutics, Inc. — Quarterly report (10-Q) — Vera Therapeutics, Inc. filed its Form 10-Q quarterly report with the SEC on August 10, 2026, detailing financial results for the quarter ended June 30, 2026. The company reported a net loss of $109.5 million, reflecting (SEC EDGAR, 2026-08-10)
• Vera Therapeutics, Inc. — Form 8-K: 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits — Vera Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 10, 2026. The filing was made under Item 2.02, Results of Operations and Financial Condition, and Item 9.01, Financial S (SEC EDGAR, 2026-08-10)
• Complement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight — The C3G treatment market across the seven major markets was valued at approximately USD 1 billion in 2025 and is projected to expand at a compound annual growth rate of 28% through 2036, driven by significant unmet need (PR Newswire, 2026-07-16)
• Vera Therapeutics, Inc. — Form 8-K: 5.02 Departure/Election of Directors or Officers — ```json { "summary": "Vera Therapeutics, Inc. filed a Form 8-K on July 9, 2026, disclosing a change in its board of directors or executive officers under Item 5.02. The filing indicates a departure or election of direc (SEC EDGAR, 2026-07-09)
• 🔎 Under the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDA — Vera Therapeutics shares rose approximately 8% on Tuesday after the U.S. Food and Drug Administration approved the company's kidney-disease drug, Trutakna. The treatment is indicated for IgA nephropathy, a disease affect (The Wall Street Journal, 2026-07-07)

Explore more

Interactive VERA chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs